Bioage Labs Stock Performance
| BIOA Stock | 20.05 0.07 0.35% |
BioAge Labs holds a performance score of 22 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.46, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioAge Labs' returns are expected to increase less than the market. However, during the bear market, the loss of holding BioAge Labs is expected to be smaller as well. Use BioAge Labs total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to analyze future returns on BioAge Labs.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioAge Labs are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, BioAge Labs sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.84) | Five Day Return 4.88 | Year To Date Return 55.73 | Ten Year Return 9.12 | All Time Return 9.12 |
1 | Disposition of 20000 shares by Ashworth Andrew P. of BioAge Labs, at 7.05 subject to Rule 16b-3 | 11/28/2025 |
2 | BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor | 12/04/2025 |
3 | Disposition of 18000 shares by Rubin Paul D of BioAge Labs, at 12.0 subject to Rule 16b-3 | 12/09/2025 |
4 | BioAge Labs, Inc. Class Action The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 ... | 12/31/2025 |
5 | Disposition of 7433 shares by Rubin Paul D of BioAge Labs at 12.8468 subject to Rule 16b-3 | 01/02/2026 |
6 | BioAge Labs Shares Gap Up Time to Buy | 01/07/2026 |
7 | Institutional investors are BioAge Labs, Inc.s biggest bettors and were rewarded after last weeks US51m market cap gain | 01/12/2026 |
8 | Acquisition by Goldstein Dov A Md of 3542 shares of BioAge Labs at 4.38 subject to Rule 16b-3 | 01/16/2026 |
9 | Wall Street Zen Upgrades BioAge Labs to Hold | 01/20/2026 |
10 | BioAge Announces Pricing of Upsized 115.0 Million Public Offering | 01/22/2026 |
11 | BioAge Labs initiated with an Overweight at Piper Sandler - TipRanks | 01/27/2026 |
12 | Acquisition by Goldstein Dov A Md of 3541 shares of BioAge Labs at 4.38 subject to Rule 16b-3 | 01/30/2026 |
13 | Disposition of 7433 shares by Rubin Paul D of BioAge Labs at 18.75 subject to Rule 16b-3 | 02/02/2026 |
14 | Morgan Stanley Boosts Price Target on BioAge Labs to 23 From 12, Keeps Equalweight Rating - marketscreener.com | 02/04/2026 |
| Begin Period Cash Flow | 25 M | |
| Total Cashflows From Investing Activities | -366 K | |
| Free Cash Flow | -51.9 M |
BioAge Labs Relative Risk vs. Return Landscape
If you would invest 749.00 in BioAge Labs on November 8, 2025 and sell it today you would earn a total of 1,249 from holding BioAge Labs or generate 166.76% return on investment over 90 days. BioAge Labs is currently generating 1.8424% in daily expected returns and assumes 6.5328% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than BioAge, and 63% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioAge Labs Target Price Odds to finish over Current Price
The tendency of BioAge Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 20.05 | 90 days | 20.05 | about 7.37 |
Based on a normal probability distribution, the odds of BioAge Labs to move above the current price in 90 days from now is about 7.37 (This BioAge Labs probability density function shows the probability of BioAge Stock to fall within a particular range of prices over 90 days) .
BioAge Labs Price Density |
| Price |
Predictive Modules for BioAge Labs
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioAge Labs. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioAge Labs Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioAge Labs is not an exception. The market had few large corrections towards the BioAge Labs' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioAge Labs, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioAge Labs within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.63 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 4.70 | |
Ir | Information ratio | 0.26 |
BioAge Labs Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioAge Labs for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioAge Labs can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioAge Labs is way too risky over 90 days horizon | |
| BioAge Labs appears to be risky and price may revert if volatility continues | |
| BioAge Labs has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (71.11 M) with loss before overhead, payroll, taxes, and interest of (3.74 M). | |
| BioAge Labs currently holds about 4.63 M in cash with (51.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| BioAge Labs has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Morgan Stanley Boosts Price Target on BioAge Labs to 23 From 12, Keeps Equalweight Rating - marketscreener.com |
BioAge Labs Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioAge Stock often depends not only on the future outlook of the current and potential BioAge Labs' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAge Labs' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.7 M | |
| Cash And Short Term Investments | 354.3 M |
BioAge Labs Fundamentals Growth
BioAge Stock prices reflect investors' perceptions of the future prospects and financial health of BioAge Labs, and BioAge Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAge Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (11.27) % | ||||
| Current Valuation | 560.58 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Price To Earning | (0.84) X | ||||
| Price To Book | 3.00 X | ||||
| Price To Sales | 142.19 X | ||||
| Gross Profit | (3.74 M) | ||||
| EBITDA | (68.58 M) | ||||
| Net Income | (71.11 M) | ||||
| Cash And Equivalents | 4.63 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 8.7 M | ||||
| Debt To Equity | 172.10 % | ||||
| Current Ratio | 1.35 X | ||||
| Book Value Per Share | 7.74 X | ||||
| Cash Flow From Operations | (51.52 M) | ||||
| Earnings Per Share | 13.78 X | ||||
| Market Capitalization | 841.31 M | ||||
| Total Asset | 358.23 M | ||||
| Retained Earnings | (252.81 M) | ||||
| Working Capital | 329.33 M | ||||
| Current Asset | 10.84 M | ||||
| Current Liabilities | 29.68 M | ||||
About BioAge Labs Performance
By analyzing BioAge Labs' fundamental ratios, stakeholders can gain valuable insights into BioAge Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioAge Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioAge Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.25) | (0.24) |
Things to note about BioAge Labs performance evaluation
Checking the ongoing alerts about BioAge Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioAge Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioAge Labs is way too risky over 90 days horizon | |
| BioAge Labs appears to be risky and price may revert if volatility continues | |
| BioAge Labs has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (71.11 M) with loss before overhead, payroll, taxes, and interest of (3.74 M). | |
| BioAge Labs currently holds about 4.63 M in cash with (51.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| BioAge Labs has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Morgan Stanley Boosts Price Target on BioAge Labs to 23 From 12, Keeps Equalweight Rating - marketscreener.com |
- Analyzing BioAge Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAge Labs' stock is overvalued or undervalued compared to its peers.
- Examining BioAge Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioAge Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAge Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioAge Labs' stock. These opinions can provide insight into BioAge Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioAge Stock analysis
When running BioAge Labs' price analysis, check to measure BioAge Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAge Labs is operating at the current time. Most of BioAge Labs' value examination focuses on studying past and present price action to predict the probability of BioAge Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAge Labs' price. Additionally, you may evaluate how the addition of BioAge Labs to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |